AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx’s suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio..

AbTherx, Inc.是一家拥有创新转基因技术的生物技术公司，这些技术能够促进和加速抗体发现。该公司今天宣布与Spice Biotechnologies达成多项目抗体发现合作。此次合作将利用AbTherx的一系列创新Atlas™小鼠技术，针对Spice Bio选定的目标提供抗体。

AbTherx’s antibody discovery platform is built on two decades of experience and utilizes evolutionary intelligence to identify diverse and developable human antibody sequences. This collaboration leverages AbTherx’s novel, patent-pending Atlas Full Human Diversity Mouse, an updated industry standard with a strong IP position that generates fully human antibodies with the affinity and diversity required for efficient, successful drug development.

AbTherx的抗体发现平台建立在二十年的经验基础上，利用进化智能来识别多样化且可开发的人类抗体序列。此次合作利用了AbTherx新颖的、正在申请专利的Atlas全人源多样性小鼠，这一更新的行业标准具有强大的知识产权地位，能够生成具备高效、成功药物开发所需亲和力和多样性的全人源抗体。

It also utilizes the Binary Fixed Light Chain Transgenic Mouse which enables native-like IgG bispecific antibodies that improve manufacturability and developability. Through these innovative technologies and a deeply collaborative partnering model, AbTherx uniquely enables startups to efficiently manage resources, timelines, and technical risk. .

它还利用了二元固定轻链转基因小鼠，这种小鼠能够产生类似天然的 IgG 双特异性抗体，从而提高制造性和可开发性。通过这些创新技术和深度协作的合作伙伴模式，AbTherx 独特地帮助初创企业高效管理资源、时间表和技术风险。

Spice Bio was founded by Alan J. Korman, a globally recognized leader in immunology and cancer research. With over 30 years of experience in drug development, Dr. Korman has shaped groundbreaking advancements in the field, most recently serving as an executive at Vir Biotechnology and Bristol Myers Squibb.

Spice Bio 由全球公认的免疫学和癌症研究领域领导者 Alan J. Korman 创立。Korman 博士在药物开发方面拥有超过 30 年的经验，推动了该领域的突破性进展，最近曾担任 Vir Biotechnology 和百时美施贵宝的高管。

Dr Korman led the discovery of a revolutionary approach to cancer immune therapy and immune checkpoint blockade, which has driven the development and approval of several groundbreaking oncology drugs. Working with AbTherx cofounders at Medarex and BMS, Dr. Korman found incredible success discovering and developing the world’s first immune checkpoint inhibitors, YERVOY® (ipilimumab) and OPDIVO® (nivolumab)..

科曼博士领导发现了一种革命性的癌症免疫疗法和免疫检查点阻断方法，这推动了多种突破性肿瘤药物的开发与批准。在Medarex和BMS与AbTherx的共同创始人合作期间，科曼博士取得了惊人的成功，发现了世界上首个免疫检查点抑制剂——YERVOY®（伊匹木单抗）和OPDIVO®（纳武单抗），并主导了它们的开发。

“Over the last 20 years, the Spice Bio team has had an incredible track record of creating successful life-saving drugs in partnership with some of our AbTherx cofounders. Because of this long, productive history, we are particularly excited to partner with Dr. Korman again in his new venture to create the next generation of immunotherapy drugs,” said Justin Mika, Chief Executive Officer of AbTherx.

“在过去的20年里，Spice Bio团队与我们一些AbTherx联合创始人合作，创造了多款成功的救命药物，成绩斐然。基于这一段长久且富有成效的历史，我们特别兴奋能够再次与科曼博士合作，在他的新项目中打造下一代免疫治疗药物，”AbTherx首席执行官贾斯汀·米卡表示。

“AbTherx is uniquely positioned to lead the next wave of antibody therapeutics with continuous innovation in antibody discovery technology, deep experience in antibody discovery, and startup-friendly partnering models.”          .

“AbTherx凭借在抗体发现技术上的持续创新、深厚的抗体发现经验以及对初创企业友好的合作模式，具备引领下一代抗体治疗浪潮的独特优势。”

From top 10 pharmaceutical companies to virtual startups, leading organizations in antibody therapeutics have rapidly adopted the AbTherx platform, resulting in over 50 initiated programs across over a dozen partners in the past nine months. Under the terms of the agreement, Spice Bio has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.

从全球前十大制药公司到虚拟初创公司，抗体治疗领域的领先机构迅速采用了AbTherx平台，使得在过去九个月中，已有十余家合作伙伴启动了超过50个项目。根据协议条款，Spice Bio拥有开发和商业化合作产生的治疗性抗体的权利。

AbTherx will receive research payments and is eligible to receive downstream clinical and commercial milestone payments, as well as royalties on net sales of products..

AbTherx将获得研究款项，并有资格获得下游临床和商业里程碑款项，以及产品净销售额的特许权使用费。

About AbTherx

关于AbTherx

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate.

AbTherx 正在通过革命性的技术推动医学发展，这些技术加速并实现了治疗性抗体的发现。通过与吉利德科学公司（Gilead Sciences）的独家授权，AbTherx 推出了 Atlas™ 小鼠，这是一套设计用于实现无与伦比性能和操作自由的新型转基因技术。

For over 20 years, a core group of AbTherx’s scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines.

二十多年来，AbTherx 的核心科学家团队通力合作，不断突破抗体发现技术的界限，成功开展了 1,000 多项发现计划，并开发出 13 种已上市的治疗药物。AbTherx 行业领先的团队创造变革性解决方案，以克服交付创新药物时面临的最严峻挑战。

Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit www.abtherx.com..

致力于使其技术为所有人所用，AbTherx 提供灵活的合作模式，满足各种规模药物开发者的需求。欲了解更多信息，请访问 www.abtherx.com。

Media Contact

媒体联系人

Stacey Borders

斯泰西·博德斯

stacey@abtherx.com

stacey@abtherx.com

Source: abtherx.com

来源：abtherx.com